Literature DB >> 15109530

Distinct cellular origins of primary effusion lymphoma with and without EBV infection.

Rifat Hamoudi1, Tim C Diss, Eric Oksenhendler, Langxing Pan, Antonino Carbone, Valeria Ascoli, Chris Boshoff, Peter Isaacson, Ming-Qing Du.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with three distinct lymphoproliferative disorders: primary effusion lymphoma (PEL), multicentric Castleman's disease (MCD) and germinotropic lymphoproliferative disorder (GLD). KSHV positive lymphocytes in GLD and in most cases of PEL are co-infected by Epstein-Barr virus (EBV) and these viral double positive cells harbour mutated rearranged immunoglobulin (Ig) genes, suggesting that they originate from germinal centre or post-germinal centre B-cells. In contrast, KSHV positive cells in MCD are invariably negative for EBV, do not carry Ig gene mutation and are believed to originate from naïve IgMlambda expressing B-cells. Interestingly, one EBV negative PEL (BC3) also lacks Ig gene mutation, raising the question whether KSHV preferentially targets naïve B-cells in the absence of EBV. We compared the cellular origin of PEL with and without EBV infection by analysis of Ig gene mutation. High molecular weight DNA from 17 PELs was subjected to PCR of the rearranged Ig heavy and light chain genes. Successful amplification was achieved from eight cases (four EBV positive and four EBV negative) and the PCR products were sequenced. All four EBV positive PEL showed variable levels of mutation in their rearranged V(H) or V(L) genes, ranging from 4 to 7%. In contrast, two of the four EBV negative PELs including BC3 displayed absence of mutation in their rearranged Ig genes. Our results indicate that EBV positive PELs are derived from germinal centre or post-germinal centre B-cells, whereas EBV negative PELs may originate from either germinal/post-germinal centre or naïve B-cells.

Entities:  

Mesh:

Year:  2004        PMID: 15109530     DOI: 10.1016/j.leukres.2003.08.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.

Authors:  Semra Kati; Edward H Tsao; Thomas Günther; Magdalena Weidner-Glunde; Thomas Rothämel; Adam Grundhoff; Paul Kellam; Thomas F Schulz
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

Review 2.  Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.

Authors:  M-Q Du; C M Bacon; P G Isaacson
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

3.  HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.

Authors:  Amy Chadburn; Jonathan Said; Dita Gratzinger; John K C Chan; Daphne de Jong; Elaine S Jaffe; Yasodha Natkunam; John R Goodlad
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 4.  KSHV/HHV8-mediated hematologic diseases.

Authors:  Ethel Cesarman; Amy Chadburn; Paul G Rubinstein
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

5.  Human Immunodeficiency Virus (HIV)-Negative and Human Herpes Virus-8 (HHV-8)-Positive Primary Effusion Lymphoma: A Case Report and Review of the Literature.

Authors:  Sonay Güven Karataş; Reyhan Bayrak; Ozlem Sahin Balçık; Kadir Serkan Yalçın; Esra Atıcı; Umit Akyıldız; Ali Koşar
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

6.  Expansion of murine gammaherpesvirus latently infected B cells requires T follicular help.

Authors:  Christopher M Collins; Samuel H Speck
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

7.  Characterization of Kaposi's Sarcoma-Associated Herpesvirus-Related Lymphomas by DNA Microarray Analysis.

Authors:  Keiji Ueda; Eriko Ohsaki; Kazushi Nakano; Xin Zheng
Journal:  Leuk Res Treatment       Date:  2011-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.